Drugs / SAMITAL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01674374 | May 2013 → Jul 2015 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, mucositis, nasal cavity and paranasal sinus squamous cell carcinoma +4 | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT01941992 | Dec 2012 → Dec 2016 | chemotherapy-induced oral mucositis, head and neck squamous cell carcinoma | Veneto Institute of Oncology IRCCS | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAMITAL | “SAMITAL (Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules) has on the management of mucositis” NCT01674374 ↗ |
| Route | Oral | “patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules orally (PO)” NCT01674374 ↗ |